Filing Flows › Tvardi Therapeutics (TVRD) › Next earnings date
Tvardi Therapeutics (TVRD) earnings on Nov 12, 2026: what to expect
Tvardi Therapeutics (TVRD) is expected to report earnings on Nov 12, 2026 (estimated), in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.57 (−$1.06 to −$0.28, 8 estimates), against −$0.59 a year ago. It beat the EPS estimate in 33% of the quarters on record; Filing Flows' model gives it a 60% chance of beating next time.
What to watch
Last quarter (Q1 2025) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.59, against the analysts' −$0.57.
The last report
Tvardi Therapeutics reported revenue of $2.6M for the first quarter 2025 (+20% Y/Y), net loss $4.9M: Other revenue $1.3M, Collaborative revenue $1.2M, Clinical compound revenue $48K. How it makes money → · Every quarter →
Tvardi Therapeutics' latest quarter
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
When does TVRD report earnings?
Tvardi Therapeutics is expected to report on Nov 12, 2026 (estimated).
What are analysts expecting from Tvardi Therapeutics?
EPS of −$0.57 for the quarter.
Does Tvardi Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 33% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.